MARKET

LRMR

LRMR

Larimar Therapeutics Inc
NASDAQ
3.340
+0.090
+2.77%
After Hours: 3.510 +0.17 +5.09% 19:52 01/17 EST
OPEN
3.320
PREV CLOSE
3.250
HIGH
3.389
LOW
3.210
VOLUME
527.36K
TURNOVER
--
52 WEEK HIGH
13.68
52 WEEK LOW
3.010
MARKET CAP
213.11M
P/E (TTM)
-2.9008
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LRMR last week (0113-0117)?
Weekly Report · 19h ago
Weekly Report: what happened at LRMR last week (0106-0110)?
Weekly Report · 01/13 12:00
SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's Ataxia
NASDAQ · 01/08 15:24
Solid Biosciences stock jumps 11% post-market on FDA update
Seeking Alpha · 01/07 22:23
Weekly Report: what happened at LRMR last week (1230-0103)?
Weekly Report · 01/06 12:11
Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better
Seeking Alpha · 01/03 22:49
Weekly Report: what happened at LRMR last week (1223-1227)?
Weekly Report · 12/30/2024 12:03
Weekly Report: what happened at LRMR last week (1216-1220)?
Weekly Report · 12/23/2024 12:11
More
About LRMR
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. It intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.

Webull offers Larimar Therapeutics Inc stock information, including NASDAQ: LRMR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LRMR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LRMR stock methods without spending real money on the virtual paper trading platform.